Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-2512

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-2512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

A forest plot chart illustrating the geometric mean ratios with 90% confidence intervals for Cmax and AUC pharmacokinetic parameters of Desvenlafaxine in populations with varying degrees of renal and hepatic impairment, as well as by gender and age groups (65-75 years and over 75 years). The x-axis shows change relative to reference, ranging from 0.5 to 3.5.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

A chart showing the geometric mean ratio with 90% confidence intervals for pharmacokinetic parameters of desvenlafaxine when co-administered with the CYP3A4 inhibitor ketoconazole. The variables include Cmax and AUC, with change relative to reference values plotted on the x-axis from 0.5 to 2.0.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

A figure showing the geometric mean ratio with 90% confidence intervals for changes in pharmacokinetic parameters (Cmax, AUC, AUCinf) of various interacting drugs including Desipramine, Midazolam, Tamoxifen, and Aripiprazole at different dosages, reflecting their interaction with Desvenlafaxine. The x-axis represents change relative to reference values.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

A Kaplan-Meier survival curve chart showing the estimated proportion of patients with relapse over time in days from randomization. Two groups are compared: one treated with Desvenlafaxine 50 mg (solid blue line) and one with placebo (dashed red line). The y-axis shows the percentage of patients with relapse, ranging from 0% to 50%, while the x-axis indicates time up to approximately 190 days.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

A line graph showing the estimated proportion of patients with relapse over time (days from randomization) comparing Desvenlafaxine and Placebo. The y-axis represents the proportion of patients with relapse (%) from 0 to 50%, and the x-axis represents time in days up to 200. The graph includes two lines: a blue solid line for Desvenlafaxine and a red dashed line for Placebo.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Chemical structure diagram of desvenlafaxine shown with molecular components, including aromatic rings, hydroxyl groups, dimethylamine, and carboxylic acid groups, along with a water molecule (H2O).*

FDA Label Image

Label (Lbl713352512)

The label for Desvenlafaxine Extended-Release Tablets 100 mg, a human prescription drug in extended-release oral tablet form. The label displays the NDC 71335-2512 and indicates a package of 30 tablets. The product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Rubicon Research Private Limited. Storage instructions and usage warnings are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.